The Drugs.com Monthly Update Podcast

In our August 2026 episode of Drugs.com Monthly Update, we review the latest round of FDA approvals bringing new therapeutic strategies to patients and prescribers. mFLUSIVA (influenza vaccine, mRNA): A new mRNA-based seasonal flu vaccine approved for the prevention of influenza disease in adults 50 years of age and older. Orzeyful (oveporexton): An innovative orexin receptor 2 agonist approved fo...

This July 2026 Drugs.com Monthly Update covers several new FDA approvals that provide novel treatment options and expand therapeutic possibilities. Gwyn Lo (ethinyl estradiol and norelgestromin): A new once-weekly transdermal patch providing low-dose estrogen and progestin for pregnancy prevention. Lytenava (bevacizumab-vikg): The first FDA-approved ophthalmic formulation of bevacizumab for patien...

This month, we're exploring advances across multiple therapeutic areas. We cover Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers. Lumvoa (veligrotug-vvze): Approved for thyroid eye disease, Lumvoa is an IGF-1R inhibitor that offers significant improvements in TED symptoms, with notable early effectiveness. Utebzi (tebipenem pivoxil): Th...

In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options. Veppanu (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data. Trimbow (beclomethasone dipropionat...

In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments. Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements. Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediat...

In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes.  Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials. Icotyde (icotrokinra): The first oral...

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and...

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin. Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval fo...

This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up. Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials...

In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike. Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasiv...

This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes. Rybelsus (semaglutide): Exploring its new role in cardi...

Discover the latest in pharmaceutical advancements with our September 2025 roundup. We're covering newly approved treatments like Rhapsido for chronic spontaneous urticaria, Palsonify for acromegaly, and Inluriyo for ESR1-mutated breast cancer. Learn about groundbreaking therapies, their impacts on patient care, and what these mean for healthcare professionals and patients alike. Rhapsido (remibru...

August 2025 brought significant advances in therapies for conditions ranging from metabolic liver disease to pediatric migraine prevention and beyond. Tune in as we delve into key FDA approvals like Novo Nordisk's Wegovy for MASH, Tonmya for fibromyalgia, and Ajovy's pediatric migraine approval, and explore their implications in clinical practice. Wegovy (semaglutide) for metabolic liver disease:...

This month we explore groundbreaking FDA approvals including Ekterly for hereditary angioedema, Anzupgo for chronic hand eczema, and the new dosing regimen of Kisunla for Alzheimer’s. We’ll discuss the mechanisms, patient impacts, and data that drive these advancements. Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and...

This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas. Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65. Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in...